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Kawasaki disease (KD) is a self-limited systemic inflammatory illness, and coro-
nary artery lesions (CALs) are a major complication determining the prognosis of 
the disease. Epidemiologic studies in Asian children suggest that the etiologic 
agent(s) of KD may be associated with environmental changes. Laboratory findings 
are useful for the diagnosis of incomplete KD, and they can guide the next-step in 
treatment of initial intravenous immunoglobulin non-responders. CALs seem to de-
velop in the early stages of the disease before a peak in inflammation. Therefore 
early treatment, before the peak in inflammation, is mandatory to reduce the risk of 
CAL progression and severity of CALs. The immunopathogenesis of KD is more 
likely that of acute rheumatic fever than scarlet fever. A hypothetical pathogenesis 
of KD is proposed under the premise of a “protein homeostasis system”; where in-
nate and adaptive immune cells control pathogenic proteins that are toxic to host 
cells at a molecular level. After an infection of unknown KD pathogen(s), the 
pathogenic proteins produced from an unknown focus, spread and bind to endothe-
lial cells of coronary arteries as main target cells. To control the action of pathogen-
ic proteins and/or substances from the injured cells, immune cells are activated. Ini-
tially, non-specific T cells and non-specific antibodies are involved in this reaction, 
while hyperactivated immune cells produce various cytokines, leading to a cytokine 
imbalance associated with further endothelial cell injury. After the emergence of 
specific T cells and specific antibodies against the pathogenic proteins, tissue injury 
ceases and a repair reaction begins with the immune cells.
Key Words:    Kawasaki disease, coronary artery lesions, laboratory parameters, in-
travenous immunoglobulin, non-responders, pathogenesis, treatment
INTRODUCTION
 
Kawasaki disease (KD) is a self-limiting systemic inflammatory disease that oc-
curs predominantly in children younger than 5 years of age.1 Clinical manifesta-
tions of KD include prolonged fever (1-2 weeks, mean 10-11 days), conjunctival 
injection, oral lesions, polymorphous skin rashes, extremity changes, and cervical 
lymphadenopathy, all of which comprise diagnostic criteria. In addition, arthritis, Kawasaki Disease: A Hypothetical Pathogenesis
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eters; thus, laboratory findings are helpful for diagnosing 
incomplete KD and evaluating patients for early prediction 
of IVIG non-responsiveness. Although some score systems 
for early detection of IVIG non-responders with a higher 
risk of CALs have been developed,17,18 further studies are 
needed for the early detection and proper treatment of ini-
tial IVIG non-responders.
In this article, a brief review of the epidemiologic, clini-
cal and laboratory characteristics of KD, as well as the poli-
cy of our institution for initial IVIG non-responders accord-
ing to the changes in laboratory findings after IVIG infusion 
are introduced. We also propose a new concept for the im-
munopathogenesis for KD under the premise of a “protein 
homeostasis system” of the host.  
   
EPIDEMIOLOGIC AND ETIOLOGIC 
ASPECTS OF KAWASAKI DISEASE
Since KD was first seen in the early 1960’s in Japan,1 KD 
has been recognized worldwide. Epidemiological studies in 
Far East Asian countries including Japan, Korea, Taiwan and 
China have revealed that KD is a new disease with similar 
epidemiologic patterns in these countries; after the initial ap-
pearance of KD, the incidence of KD showed a gradual in-
crease for a decade up to a nationwide occurrence (becoming 
an endemic disease), and then KD occurred everywhere with 
relatively constant but slowly growing rates.19-21 The appear-
ance and subsequent incidence of KD may be associated 
with the time of industrialization and westernization of 
these countries.13 Therefore, it could be postulated that in 
the past, KD (infantile polyarteritis nodosa) might have ap-
peared in Western countries around the beginning of the 20th 
century. Throughout the past decade, KD has appeared in 
rapidly modernizing countries, including India, where KD is 
more prevalent in modernized cities of economically higher 
income.22 Environmental factors such as improved public 
hygiene or westernized lifestyles may be associated with the 
emergence and establishment of KD. In South Korea, al-
though yearly incidence rates show no remarkable spatial 
(geographical) and temporal (seasonal) differences,19 recent-
ly, clinical features of KD seem to be changing to milder 
phenotypes with greater numbers of incomplete KD cases.23 
In children of other ethnicities, it was also reported that the 
clinical features of a disease in an outbreak seem to differ 
from previous outbreaks.24,25 These findings suggest that the 
etiology of KD may not be due to a single agent and raise 
aseptic meningitis, anterior uveitis, gall bladder hydrops, 
urethritis and lung involvement can be seen.2 Some more 
severely affected patients show cardiac complications, par-
ticularly coronary artery lesions (CALs) such as aneurysms 
and ectasias, which develop in approximately one quarter 
of untreated children and 5-10% of intravenous immuno-
globulin (IVIG) treated children.3,4 These diverse systemic 
inflammations (mainly vasculitis) may be caused by in-
flammatory mediators with circulating immune cells (neu-
trophils, lymphocytes, natural killer cells and monocytes), 
and there may be various immune cell infiltrations in all af-
fected pathologic lesions from affected lymph nodes to skin 
rashes. Particularly, a larger number of T cells (more CD8 
cells than CD4 cells), large mononuclear cells, macro-
phages and plasma cells, with a smaller number of neutro-
phils, are observed in various organ tissues of fatal cases of 
acute KD.5-8 In addition, peripheral blood analysis of acute 
KD patients showed T lymphocytopenia with depressed 
CD8 T cells, increased activated CD4 T cells and depressed 
CD4+CD25+ regulatory T cells.9-11 These findings suggest 
that the majority of circulating T cells move to the patho-
logic lesions of various tissues in acute KD. Therefore, cir-
culating immune cells, especially T cells, control the in-
flammation of the majority of the affected regions of KD 
patients without sequelae, but they also may be involved in 
the progression of the disease, such as in the case of CALs. 
Epidemiological and clinical data suggest that KD is an im-
munological reaction to infectious triggers occurring in ge-
netically susceptible children. Although studies have pro-
vided hypothetical explanations for the pathogenesis of 
KD, the etiologic agents, the immunopathogenesis of the 
vasculitis, and the mechanism that underlies the predilec-
tion for coronary artery involvement in KD are largely un-
known.2,11-16 
Laboratory parameters are used for the diagnosis and 
evaluation of conditions of patients for any inflammatory 
disease. As for laboratory findings in KD, many inflamma-
tory indices change throughout the disease process; elevat-
ed levels of C-reactive protein (CRP), erythrocyte sedimen-
tation rate (ESR), leukocyte count with neutrophilia 
(lymphopenia), platelet count, alanine aminotransferase 
(ALT), aspartate aminotransferase (AST) and other inflam-
mation associated enzymes, as well as decreased levels of 
lymphocytes, albumin, hemoglobin, sodium, potassium and 
total cholesterol including high density lipoprotein choles-
terol (HDL-cholesterol) have been detected.2 The severity 
of inflammation in KD is reflected by inflammatory param-Kyung-Yil Lee, et al.
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have been implicated.15,36 Recently as a more precise genet-
ic tool, a genome-wide linkage analysis and follow-up as-
sociation study (genome-wide associated study) for the po-
tential loci and genes of susceptibility to KD have also been 
performed in several countries.37-40 The results of the genet-
ic studies may have some limitations resulting from small 
sample size, failure to replicate results in subsequent stud-
ies, and lack of precise phenotype of KD patients based on 
CAL outcomes and response to IVIG therapy.36,41 In Japan, 
Onouchi, et al.37,42 reported that the ITPKC gene which is a 
negative regulator of T-cell activation was associated with 
KD susceptibility and an increased risk of CALs. Although 
the association of the ITPKC gene in replication studies of 
other populations is controversial,39,40,43 this finding sug-
gests a relevant clue for the genetic study of KD in which 
immune reaction of T cells may have a crucial role in the 
immunopathogenesis of the disease. Recently, the Interna-
tional Kawasaki Disease Genetics Consortium has been or-
ganized and has identified many candidate genes potential-
ly related to inflammation, apoptosis and cardiovascular 
pathology.38,41 Although susceptibility to KD is polygenic, 
further studies are necessary to determine relationships be-
tween the candidate genes and functional consequences that 
lead to KD or CALs.
The etiology of KD still remains unknown, despite great 
efforts to identify the cause for nearly a half a century. The 
epidemiological characteristics of KD are so unique that it 
is difficult to find a similar model among acute infectious 
disease, including newly introduced infectious diseases 
such as retrovirus infections (acquired immunodeficiency 
syndrome) or conventional infectious diseases. Although 
many putative bacterial agents including superantigen pro-
ducing bacteria, viral agents such as Epstein-Barr virus, ret-
roviruses and coronaviruses, and other agents have been 
suggested, there was no proven single agent for KD.44-50 
Given the epidemiological and clinical characteristics of 
KD, we previously postulated that etiologic agents were 
variants of normal flora produced by environmental chang-
es.13 The microscopic structures and genomic materials be-
tween a pathogen and its related flora are nearly identical 
except for tiny genetic variations, and some pathogens can 
change to normal flora after infection in a host. It has been 
reported that the intestinal microflora in infants are different 
according to ethnic groups and environments.51,52 There-
fore, environment factors and possibly genetic factors can 
affect the distribution of microflora and induce the variants 
of normal flora. 
the possibility of changing epidemiological and clinical fea-
tures, including treatment response highlighting the need 
for enhanced surveillance.
KD has an age predilection for children from 6 months of 
age to 5 years of age, with a peak incidence in children be-
tween 6 and 24 months old. This trait has not changed since 
the emergence of KD and is reflected in all ethnic groups. 
This disposition suggests that the maturing immune system 
in early childhood is involved in the pathogenesis of KD.13 
In general, acute infectious diseases affect children of all 
ages, although the phenotypes of some infectious diseases 
are age-dependent. In viral infections such as hepatitis A vi-
rus, coronavirus (SARS) and influenza virus as well as in 
mycoplasma infections, younger children (<5 years of age) 
show less severe clinical symptoms and signs, compared to 
older children (>5 years of age) and adults.26-29 On the con-
trary, in bacterial infections such as staphylococcal pneu-
monia and tuberculosis as well as in parasitic infections 
such as malaria, younger children have a more severe clini-
cal course.30,31 In KD, older children had prolonged fever 
and a higher incidence of CALs compared to younger chil-
dren.32,33 In addition, there are early childhood immune-me-
diated hematologic disorders, showing a similar age restric-
tion as that of KD, including transient erythroblastopenia of 
childhood, autoimmune neutropenia of infancy, childhood 
immune thrombocytopenic purpura, and transient hypo-
gammaglobulinemia of infancy. These disorders may be as-
sociated with infectious insults and have a self-limited clin-
ical nature improving before 5 years of age. These findings 
suggest that the age of around 5 years old in childhood is 
the turning point of immune maturation of the host. KD may 
be regarded as among these disease categories, reflecting 
immunologic immaturity during early childhood, although 
KD has an acute immune disturbance. 
KD also has a predilection for certain ethnic groups. 
Asian children, particularly those of Japanese, Korean and 
Chinese ethnicity have the highest incidence of >10-15 
times greater than Caucasians, although KD has been re-
ported in all ethnic groups.19-21,34 The incidence for Japa-
nese-Americans living in Hawaii is similar to the incidence 
for Japanese living in Japan, supporting a genetic predispo-
sition for KD.35 With the development of the study of hu-
man genetics and genomics, molecular genetics has be-
come an area of interest for the study of KD. Many genetic 
studies in different countries have evaluated variants in can-
didate KD genes, and a number of variants, including inosi-
tol 1,4,5 triphosphate 3-kinase (ITPKC) and caspase-3, Kawasaki Disease: A Hypothetical Pathogenesis
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risk of CALs. For example, a severely affected patient who 
is persistently febrile for a week, showing constant low lev-
els of platelet with high levels of AST and ALT in follow-
up examination, may still not have reached the peak stage 
of inflammation, suggesting a higher possibility of more se-
vere CALs. 
Laboratory findings are now mandatory for diagnosis of 
incomplete KD.2 Patients who do not fulfill conventional 
diagnostic criteria have been diagnosed as having incom-
plete KD, with <4 of the principal clinical features of KD. 
LABORATORY PARAMETERS IN KD
The severity of systemic inflammation in KD varies, result-
ing in different clinical phenotypes and changes of laboratory 
parameters among the affected children. A large number of 
patients have a mild clinical course with shortened fever du-
ration and no CALs, but some severely affected patients 
show prolonged fever duration of up to 2-3 weeks, multiple 
coronary artery aneurysms and even death. Laboratory 
findings reflect the severity of systemic inflammation in 
KD, with concurrent increase or decrease of laboratory val-
ues. To understand the natural course of KD and the chang-
es of laboratory indices during the febrile period is very im-
portant for the diagnosis, proper treatment and evaluation 
of KD patients. 
KD is a self-limiting disease. The total duration of fever in 
the era of non-IVIGs is 1-2 weeks (mean 10-11 days), re-
gardless of treatment with aspirin or corticosteroids.1,53,54 
Therefore, a patient who is expected to have a total fever 
duration of 11 days reaches a peak in inflammatory pro-
cesses at the sixth day after fever onset, if the periods of as-
cent to and regression from the peak are similar (Fig. 1). 
We previously evaluated the inflammatory indices in KD 
patients according to the fever duration at presentation. In-
deed, the levels of white blood cells (WBC) and neutrophil 
counts and CRP levels were highest, while the albumin and 
HDL-cholesterol levels were lowest, at the sixth day, and 
these indices showed a bell-shaped or U-shaped distribu-
tion trend based on these values at the sixth day (the peak) 
(Fig. 2).55 These findings suggest that the inflammatory pro-
cesses of KD progress to a peak, then regress to a convales-
cent stage during the febrile period. It also suggests that in 
cases of CALs, the immune cells involved in tissue destruc-
tion (endothelial damage) have a predominant role in the 
early stages and the immune cells involved in tissue repair 
have a predominant role in the late stages of KD, and the 
results are reflected by laboratory findings. The transami-
nases (AST and ALT) appear to be higher in the early days, 
and markedly decrease after the peak stage of KD. Total 
cholesterol level may be the lowest in the early days and 
tends to increase along with the natural course of inflamma-
tion. Platelet count is well known to increase in convales-
cent stages of KD. However, platelet count may begin to 
increase at the peak stage of KD, suggesting involvement 
in tissue repair (Fig. 2). These findings may be useful for 
evaluation of the severity of patients who have the highest 
Fig. 1. Inflammatory intensities of KD patients during febrile periods. a, b 
and c: Inflammatory intensities of the mildly affected patients (a), moder-
ately affected patients (the average of the patients) (b), and the severely af-
fected patients (c). d: An imaginary threshold line of coronary artery le-
sions. The severely affected patients reach the threshold line earlier, and 
before the peak in inflammation. KD, Kawasaki disease.
Fig. 2. Suspected patterns in the change of laboratory parameters during 
febrile period. a: bell shaped pattern; CRP, WBC, neutrophil and CPK, b: U 
shaped pattern; albumin and HDL-cholesterol, c: little changes; ESR and 
LDH, d: Steadily decrease; AST, ALT, e: steadily increase: total cholesterol, 
f: increase after the peak; platelet. CRP, C-reactive protein; WBC, white 
blood cells; CPK, creatine phosphokinase; HDL, high density lipoprotein; 
ESR, erythrocyte sedimentation rate; LDH, lactic dehydrogenase; ALT, ala-
nine aminotransferase; AST, aspartate aminotransferase. 
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CALs, and were treated with IVIG.2,57,58 However, now 
IVIG is recommended for all KD patients. IVIG has a po-
tent anti-inflammatory effect on KD although its mode of 
action is unknown. It has been reported that approximately 
10-15% of KD patients are IVIG non-responders.17,18,25,59-63 
Early detection of IVIG non-responsiveness through labo-
ratory values is a reasonable and simple method for the eval-
uation of severity of KD and for the selection of severely af-
fected patients who need early intensive treatment. For this 
purpose, there have been a number of previous reports of pu-
tative predictive variables of IVIG non-responders. Laborato-
ry markers including CRP, neutrophil differential including 
bands, albumin, sodium, hemoglobin, platelets, lactic dehy-
drogenase (LDH), total bilirubin, γ-GTP, ALT, and AST have 
been reported to differ significantly between IVIG non-re-
sponders and responders before IVIG infusion.17,18,25,59-63 
These different laboratory predictors with the score systems 
for IVIG non-responsiveness,17,18 and the earlier Harada 
score system for risk of CALs may have a limitation result-
ing from confounding factors; difference of sample size,64 
the intensity of inflammation in individuals, the age of pa-
tients,32 the stage of inflammation response at presentation 
as shown in Fig. 1,55 and possibly ethnicity.25,65 Some stud-
ies suggest that earlier IVIG treatment, particularly before 
day 5 of illness is associated with an increased risk of non-
response to IVIG.17,18,25,63 It is plausible that IVIG non-re-
sponders might have more severe inflammation and more 
florid clinical symptoms and signs, and consequently they 
may be diagnosed and treated earlier.18 Because of the limi-
tations of early prediction for IVIG non-responders, some 
study groups have tried early aggressive treatment for pre-
vention of CALs with IVIG (2 g/kg), aspirin, and methyl-
prednisolone (30 mg/kg) or infliximab. However the results 
of these studies are controversial.41,56,66,67 This treatment pol-
icy also has some obstacles such as overtreatment of patients 
with mild clinical course; 85-90% of the patients respond to 
initial IVIG treatment (2 g/kg). Furthermore it was reported 
that ~80% of the patients responded to a medium-dose of 
IVIG (1 g/kg),68 although high doses of IVIG are more effec-
tive in preventing CALs.69 Thus, early detection of the se-
verely affected patients among all KD patients and prompt 
further treatment of these patients is necessary because CALs 
develop and progress before the peak stage of the disease.
IVIG down-regulates nearly all inflammatory laboratory 
parameters except ESR including total WBC and neutro-
phil count, CRP, AST, ALT, CPK and LDH in IVIG respond-
ers. IVIG increases ESR artificially through interference 
Because incomplete KD is more common in young infants 
than in older children,2,32,33 clinicians must make every ef-
fort for accurate diagnosis and timely treatment of these 
young patients. The American Heart Association provided 
an algorism for diagnosis of incomplete KD in 2004. Pa-
tients with fever lasting longer than 5 days with 2 or 3 of 
the diagnostic signs of KD should be evaluated for system-
ic inflammation daily if possible. Initially CRP (>3 mg/dL) 
and ESR (>40 mm/h) levels and complementary laboratory 
findings including albumin <3.0 g/dL, anemia for age, ele-
vation of ALT, platelets after 7 days >450000/mm3, WBC 
count >15000/mm3, and urine >10 WBC/high-power field, 
should be reviewed. Patients who fulfill more than 3 of these 
complementary indices can be treated with IVIG as having 
incomplete KD followed by echocardiography. Although lab-
oratory findings in KD are non-diagnostic, they may prove 
useful in the diagnosis of incomplete Kawasaki disease.2  
It is reported that ~25% of untreated patients and ~5% of 
IVIG treated patients are affected with CALs.3,4 Therefore, 
we were able to determine an imaginary line for the thresh-
old of CALs during the natural course of systemic inflam-
mation in KD, and we assumed that IVIG could lower the 
peak point of the inflammation curve (Fig. 1). CALs begin 
at the point where the threshold line and the curve of in-
flammation intersect, and more severely affected patients 
reach the threshold line earlier before the peak stage of in-
flammation (arrows in Fig. 1). Early and extensive treat-
ment with IVIG (2 g/kg) and methylprednisolone pulse 
therapy (30 mg/kg) may not prevent CALs development in 
some severely affected patients,56 and small CALs can prog-
ress to huge giant aneurysms after defervescence induced 
by various treatments. These findings suggest that the se-
verity of CALs is determined in the early period, before the 
peak stage of KD. Therefore, early IVIG treatment before 
the peak stage is mandatory to reduce the risk of CALs and 
the progression of CALs.
Higher severity of systemic inflammation in KD is re-
flected by prolonged fever duration, a higher incidence of 
CALs, a higher or lower laboratory values, and a higher 
rate of IVIG non-responsiveness. In the initial periods of 
IVIG treatment in Japan and Korea, the score system (Ha-
rada score) for evaluation of the severity of KD (a risk of 
CALs) was used to decide on IVIG treatment; WBC count 
>12000/mm3, platelet count <350000/mm3, CRP >3+, he-
matocrit <35%, albumin <3.5 g/dL, age <1 year of age, and 
male sex.57 KD patients who fulfill ≥4 of the 7 criteria were 
regarded as having severe inflammation with higher risk of Kawasaki Disease: A Hypothetical Pathogenesis
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(initial 2 g/kg, and the second-dose, 1 or 2 g/kg) and intra-
venous methylprednisolone pulse therapy (10-30 mg/kg, 
for 3 days). The dose of the second IVIG infusion (1 or 2 g/
kg) was assessed on a case-by-case basis. In general, the pa-
tients who failed to respond but whose WBC with neutro-
phil and CRP decreased following the initial IVIG treat-
ment received a further dose of 1 g/kg, whereas those  whose 
WBC count and/or CRP remained unchanged or increased 
after the initial IVIG treatment received a second IVIG dose 
of 2 g/kg. Those unresponsive to the second dose of IVIG 
received intravenous pulsed methylprednisolone (10-30 
mg/kg, for 3 days), and the dose was also determined by 
WBC and CRP levels within 24 h after the second-dose 
IVIG infusion. We have experienced no patients who re-
mained febrile after termination of this treatment schedule 
among more than 500 KD patients. We were able to induce 
defervescence within 12 days from the beginning of the ill-
ness in a majority of the IVIG non-responders (~10% of to-
tal KD patients), and only three patients were discovered to 
have giant aneurysms (>8 mm in diameter) after defervesc-
cence.58,75 Since the change of laboratory indices after IVIG 
therapy appears within 2 hrs after termination of IVIG infu-
sion71 and the majority of IVIG responders defervesce with-
in 24 hrs of IVIG treatment (2 g/kg), it may be possible to 
make a decision on commencing the next-step in treatment 
of IVIG non-responders, earlier than 24 h. With this, further 
studies in other populations should aim to optimize treat-
ment of IVIG non-responders in KD. 
For IVIG non-responders, re-infusion of IVIG (2 g/kg), 
methylprednisolone pulse therapy (30 mg/kg, for 3 days), 
infliximab (anti-TNF-α antibodies), and more powerful im-
mune-modulators such as cyclophosphamide or methotrex-
ate, and plasmapheresis have been tried.78-82 It is believed that 
severely affected KD patients destined to prolonged fever 
cannot avoid CALs in the early stage of this self-limited dis-
ease, although these treatments can induce defervescence.  
   
A HYPOTHETICAL PATHOGENESIS  
OF KD
For understanding the pathogenesis of KD, a brief review 
of resembling diseases may be helpful. Among bacterial in-
fections, scarlet fever/acute rheumatic fever (ARF) may be 
a representative disease resembling KD. Clinical manifesta-
tions of scarlet fever, etiologic agents of which are mainly 
the group A beta-hemolytic streptococci (GAS), are fever, 
with fibrinogen levels.70 In addition, IVIG has a systemic 
protein modulation effect in vivo; all proteins including al-
bumin, transferrin, apolipoprotein A1, and pro-inflammato-
ry cytokine (TNF-α and IL-6) levels were transiently de-
creased, but the levels of immunoglobulins (IgA and IgM), 
electrolytes (sodium, potassium, chloride, calcium and phos-
phorus) and serum osmolarity were not changed by IVIG 
infusion.70-72 Therefore, the beneficial effect of IVIG on KD 
may, in part, be associated with the control of the proteins 
which are involved in inflammation in various tissues of the 
host, although IVIG has multiple modes of action for im-
mune modulation.11,73
On the other hand, IVIG non-responders generally have 
persistently elevated inflammatory parameters, such as neu-
trophil counts and CRP and lower levels of albumin after 
IVIG infusion.59,74 We recently observed that IVIG non-re-
sponders have sustained abnormal laboratory parameters 
following IVIG (within 24 hrs) as well as prior to IVIG com-
pared to IVIG responders; the cut-off values of >13000/μL 
for total WBC count, >51% for neutrophil differential and 
<7.2 g/dL for total protein had reasonable sensitivity (91%, 
91% and 64%, respectively) and specificity (89%, 76% and 
78%, respectively) as independent characteristics of non-re-
sponse to IVIG.75 In addition, the kinetics of some inflam-
matory parameters following IVIG differed markedly be-
tween responders and non-responders. Among them, WBC 
count and CRP in non-responders increased or remained 
unchanged following initial IVIG infusion (2 g/kg), in con-
trast to the marked decline in these parameters in respond-
ers. Thus, clinicians can use these parameters easily and 
rapidly for the evaluation of the severity of inflammation in 
KD. The definition of IVIG non-responsiveness and the 
treatment modality for initial IVIG non-responders are not 
clearly determined among the study groups. Many study 
groups have observed the patients for 36-48 h after termi-
nation of IVIG infusion to see whether or not the patients 
showed defervescence and improvement of clinical signs. 
The non-responders also consisted of patients with a differ-
ent severity of inflammation. It was reported that 20-50% 
of initial IVIG non-responders also did not respond to a sec-
ond dose of IVIG.76,77 For these severely affected patients, 
rapid treatment may lead to a better outcome, because of 
the possibility of rapid progression of CALs in the early 
stage of the disease. In our hospital, we defined IVIG non-
responders as patients with persistent fever (≥38.0°C) over 
24 hrs after termination of IVIG infusion. Our treatment mo-
dality for IVIG non-responders is the 2-dose IVIG infusion Kyung-Yil Lee, et al.
Yonsei Med J   http://www.eymj.org   Volume 53   Number 2   March 2012 268
sis of KD is closer to that of ARF than scarlet fever. In ad-
dition, the causes of death in both acute KD and ARF are 
extensive carditis or complications from distorted cardiac 
vessels or cardiac valves. There are also rare incidences of a 
sepsis-like syndrome with multiple organ failure and the ful-
minating clinical course, which are shown in severely affect-
ed patients of GAS infections or any acute infectious dis-
eases, including viral infections. The laboratory findings in 
both diseases have revealed increased leukocytes, and CRP 
and ESR values, indicating systemic inflammation with ac-
tivated immune cells. The characteristic clinical manifesta-
tions and pathologic findings in various tissues in scarlet fe-
ver, ARF and KD may depend on different inflammatory 
mediators (proteins) and corresponding immune cells. Patho-
gens or sole pathogen-associated structural substances have 
not been identified in the pathologic lesions of KD or ARF 
(coronary artery, endocardium, and cardiac valve).86,87 Even 
in acute GAS infections, bacteria are not found in the af-
fected tissues of toxic shock syndrome or necrotizing fasci-
itis.85 Thus, toxic substances and circulating immune cells 
may be involved in the tissue injuries from these conditions. 
There are many enigmas as to the pathogenesis of KD. Par-
ticularly, as to what the etiologic substance of the systemic 
inflammation and tissue injury is, how initial inflammation 
begins, and why only some patients are affected with differ-
ent clinical severities, as in the case of ARF and APSGN af-
ter initial GAS infections, are of concern.
To solve these puzzles, we propose a new hypothesis 
based on the premise of a “protein homeostasis system” in 
the host. Mammals, including humans, have evolved through 
genes which code for proteins. All living activities from em-
bryonic development to the aging process are strictly con-
trolled by a variety of proteins at the molecular level. The 
numbers and kinds of genes (kinds of proteins) that are ac-
tivated differ according to the different organ tissue cells 
and timing of their activation. An organ specific cell pro-
duces its own specific proteins. Also, some proteins are 
produced only during the embryonic stage while some pro-
teins are produce in later stages of the life cycle of mam-
mals. For example, in genetic diseases such as neurofibro-
matosis or rare genetic prion diseases including fatal familial 
insomnia, the expression or progression of these diseases 
appears after 2-5 decades of age.88 The pathogenesis of 
these genetic diseases may be associated with transformed 
proteins, including prions, which may be toxic to nerve cells, 
and the toxic proteins should be controlled for avoidance of 
the disease in vivo. On the other hand, mammals have also 
strawberry tongue, cervical lymphadenopathy, skin rashes 
and desquamation of skins after defervescence, mimicking 
those of KD. Although some patients with GAS infection 
complain of severe clinical phenotypes including streptococ-
cal toxic shock syndrome and necrotizing fasciitis, scarlet fe-
ver is a self-limited disease, with a mean historical fever du-
ration of 6 days without antibiotic treatment.83 If enough 
doses of GAS are inoculated to every individual, nearly all 
individuals who do not have antibodies to toxins would be 
affected with scarlet fever. The immunopathogenesis of se-
vere GAS infections such as streptococcal toxic shock syn-
drome and necrotizing fasciitis remains unknown. It is sug-
gested that the streptococcal superantigens, including 
pyrogenic exotoxins, stimulate an intense proliferation and 
activation of the immune cells (T cells and macrophages), 
resulting in the production of large quantities of cytokines. 
The cytokine imbalance of a local environment may be re-
sponsible for tissue injuries and many of the clinical mani-
festations of severe, invasive GAS infections.84,85 As non-
suppurative complications, ARF and acute poststreptococcal 
glomerulonephritis (APSGN) are well-documented after 
GAS infections.83
ARF is an acute febrile disease characterized with pro-
longed fever, carditis, arthritis, skin rash (erythema margin-
ata) and chorea.86,87 ARF occurs 2-4 wks after the primary 
GBS infections of the pharynx. The majority of GAS infect-
ed patients recover uneventfully, and only some patients who 
have genetic susceptibility may be affected with ARF, simi-
lar to KD. Although ARF is a disease of which the etiologic 
agent has been proven, the immunopathogenesis of the dis-
ease remains unsolved with speculation as to an immune-
mediated disease triggered by infectious insults. One hy-
pothesis suggests that bacterial exotoxins or superantigens 
may be involved in the cardiac tissue injury through the di-
rect toxic effect on target tissues or through activated cyto-
kines. Others suggest that autoimmune reaction of immune 
cells that are sensitized to bacterial antigens may attack the 
target cells that may share epitopes with bacterial antigens 
(“molecular mimicry”).86,87 The clinical manifestations of 
ARF can appear without symptomatic GAS infections (phar-
yngitis) in a third of patients.86 Antibiotic treatment of scar-
let fever rapidly improves clinical symptoms and signs of 
the disease, but shows no effect in ARF and KD. There may, 
however, be sites (foci) in which the substances provoking 
inflammation in ARF or KD as well as in scarlet fever are 
produced and released to systemic circulation.
At this point, we can deduce that the immunopathogene-Kawasaki Disease: A Hypothetical Pathogenesis
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ies, via cytokine production, using T cell receptors (TCR) or 
via their effect on cell-bound proteins. Macrophages may 
play the most crucial role in the immune/repair system of the 
host. Also, they synchronize the communications between 
innate immune cells and adaptive immune cells in inflam-
matory reactions, and between immune cells and regenerat-
ing tissue cells in repair reactions, via a complex of cyto-
kine (protein) networks. Although the immune system of 
the mammals have been divided into the separate catego-
ries of innate immune system and adaptive immune system, 
the two immune systems work together against any internal 
or external insults in vivo. It is now accepted that the media-
tors (proteins) from innate immune reactions affect adaptive 
immune reactions.91,92 In infections of various pathogens, 
pathogen recognition receptors including Toll-like receptors 
(TLRs) and intracellular sensors which recognize compo-
nents of pathogens (pathogen-associated molecular pattern) 
of infected cells and macrophages, induce the production of 
anti-agent proteins (in case of viruses and interferons) and 
other proteins including pro-inflammatory cytokines. These 
proteins may affect the function of adaptive immune reac-
tions such as control of expression of co-stimulatory recep-
tors or activation of specific immune cells.91,92 B cells (plas-
ma cells) can produce antibodies for any proteins which are 
recognized by B cell receptors (BCRs). Theoretically, gene 
recombination of BCR genes can match all internal or ex-
ternal proteins. However, B cells cannot induce antibodies 
against small foreign proteins and a majority of self serum 
proteins. Similarly, TCRs of T cells also comprise recombi-
nation of variable TCR genes, matching nearly all peptides 
(proteins) that are constructed with 12-27 amino acids. De-
spite the more crucial role of T cells than B cells on host 
defense against invading pathogens (T cell deficiency is 
more severe compared to B cell deficiency), the role of TCRs 
is nearly unevaluated except for antigen presentation be-
tween T cells and APCs compared to B cell function. Lots 
of small peptides may exist in inflammatory lesions; how-
ever, the metabolism and role of these proteins remain to be 
evaluated. Indeed, small peptide hormones such as gonado-
trophin releasing hormone (GnRH, decapeptide), vasopres-
sin (9 peptide) and oxytocin (9 peptide) exist in vivo, and 
they have crucial roles on systemic hormonal homeostasis.93 
Furthermore in the nucleus of the cells, replication of DNA 
for cell proliferation and small microsomal RNAs, which 
regulate gene expression, may also be controlled by proteins, 
including DNA polymerases and nucleases, suggesting com-
plex mechanisms of protein homeostasis at a cell level.94 
struggled with external insults in nature. The compositions 
of various pathogens and animal toxins, such as snake ven-
om and insect venom are mainly proteins of various sizes, 
shapes and lethal doses. These toxic proteins may have their 
own affinity to different organ-tissue cells and bind to the 
receptors on the cells of the host. This toxic protein-recep-
tor binding may induce direct cell injury and/or may pro-
duce new proteins through signal transduction pathways in 
the affected cells. The substances (proteins) from injured 
cells can be released to systemic circulation and signal oth-
er immune cells. Now, it is believed that substances from 
injured cells of a specific organ tissue can induce an im-
mune reaction and subsequently be toxic to other organ 
cells or their own tissue cells, if released to the systemic cir-
culation.89,90 Matzniger proposed an interesting hypothesis 
for this basic immunological concept, the danger model. 
Herein, antigen presenting cells (APCs) can be activated by 
danger/alarm signals (initiators of inflammation) from the 
injured cells that are caused by pathogens, toxins, mechani-
cal damage, and so forth. The intracellular contents from 
necrotically died cells could potentially be a danger signal 
when released, but not that of healthy cells or by cells un-
dergoing physiological deaths (apoptosis).89 Complete re-
covery from a systemic infectious disease may be defined as 
the state in which not only etiologic agents and inflammato-
ry mediators from pathogens but also the substances pro-
duced during immune reactions including cytokines and the 
debris from the injured cells have been completely removed 
by immune cells, if those substances could be toxic to other 
tissue cells. We define these toxic proteins as “pathogenic 
proteins”, classifying external pathogenic proteins as those 
which are of the pathogen origin and internal pathogenic 
proteins as those which are of host origin, including prions. 
A strict protein control system controls the balance of pro-
teins and removes the pathogenic proteins at a molecular 
level in humans. Serum proteins including albumin, immu-
noglobulins and various hormones are maintained at constant 
levels in a steady (healthy) state by unknown protein control 
systems, and we have named these systems as “protein ho-
meostasis systems”. Here, we postulated that the immune 
system of the host is one of the protein homeostasis systems 
in vivo. The main function of immune cells at a molecular 
level is to control of a variety of proteins by recognition of 
size. Innate immune cells (neutrophils and phagocytic mono-
cytes) control larger proteins (microbes and injured cells as a 
whole), B cells control proteins via antibody production, and 
T cells control small proteins which cannot induce antibod-Kyung-Yil Lee, et al.
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corresponding immune cells, including macrophages and T 
cells, may also be involved in the pathogenesis of keloids.96 
T cells can be activated by various stimuli such as mitogens 
and monoclonal antibodies for various receptors on T cells 
in vitro, thus the mechanisms of T cells activation in vivo 
may be different in various pathologic conditions. Although 
helper T cells can be divided into functional subtypes such 
as Th1, Th2, Th17 and regulatory T (Treg) cells according 
to the cytokines produced from the T cells, it is expected 
that more T cells subtypes, which produce different cyto-
kines, may exist in different pathogenic lesions in vivo.97 
Therefore, the functions of T cells are more diverse and com-
plex than we have previously known. 
Returning to the immunopathogenesis of KD, it is postulat-
ed that systemic inflammation of KD is caused by pathogenic 
proteins which are associated with an immune reaction of an 
unknown initial infection. In this infection, a majority of the 
patients may be asymptomatic. The toxic substances pro-
duced during the immune reaction against the initial infection 
may be removed in a majority of the patients, but some pa-
tients who have a genetic defect for this feedback process 
may lead to foci for which the pathogenic proteins are pro-
duced and released into systemic circulation. Although the 
foci producing pathogenic proteins responsible for KD or 
ARF are unknown, the secondary lymphoid organs around 
the initial infection sites (tonsils, lymph nodes or Payer’s 
patches) are primary candidates (Fig. 3A). The pathogenic 
Superantigens are virulent polypeptides (proteins) that 
are produced by a variety of infectious organisms including 
gram positive streptococci and staphylococci. Superantigens 
can induce activation of many T-cell clones which have spe-
cific Vβ chains. However, in any human disease including 
KD, clinical implications of polyclonal activation of T cells 
have not been clearly explained.95
T cells together with other immune cells appear in nearly 
all pathologic lesions in early stages, before specific T-cells 
and specific antibodies appear, of infectious diseases, rheu-
matic disorders including KD and ARF, malignancies as tu-
mor infiltration lymphocytes, tissue rejection, and in the re-
pair processes of tissue injury (keloids). For example, in 
Mantoux skin tests for diagnosis of tuberculosis, skin tissue 
injury (positive result) is induced by proteins (purified pro-
tein derivatives) and corresponding immune cells, mainly T 
cells, which were previously sensitized to the proteins from 
tuberculosis bacilli or Mycobacterium bovis Bacillus 
Calmette-Guérin (BCG). Positive skin reactions can be 
abolished in states of depressed T cell function or an ex-
hausted number of T cells in cases of corticosteroid treat-
ment, systemic viral infections such as measles, and severe 
tuberculosis infections.30 Furthermore, a clean skin injuries 
such as scar revision in plastic surgery, in which there are 
no foreign proteins or pathogens, on occasion result in hy-
pertrophic scars or keloids in genetically susceptible pa-
tients. The substances (proteins) from injured skin cells and 
Fig. 3. A hypothetical pathogenesis of KD. After an infection by an unknown KD pathogen(s), substances including pathogenic proteins are 
produced in a focus (potentially secondary immune organs) (A). The substances spread and reach various tissues via systemic circulation. 
Immune cells start to control these substances, and clinical symptoms and signs begin to appear. The pathogenic proteins bind to recep-
tors of endothelial cells of coronary arteries, and this process induces cell injury and /or other protein production from endothelial cells (B). 
Immune cells recruit to the lesions to control the action of the proteins including pathogenic proteins. Initially, non-specific T cells and non-
specific antibodies are involved in this reaction, while hyperactivated immune cells produce various inflammatory cytokines and counter-
inflammatory cytokines, leading to a cytokine imbalance associated with further endothelial cell injury (C). After emergence of specific T 
cell clones and specific antibodies for pathogenic proteins, tissue injury ceases and a repair reaction begins with the immune cells (D). KD, 
Kawasaki disease.
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stances including antibodies may be different from KD. We 
previously used this hypothesis to explain the immunopatho-
genesis of acute lung injury in Mycoplasma pneumoniae (M. 
pneumoniae) and influenza virus infections.98,99 For the 2009 
H1N1 influenza virus infection, the severity of pneumonia 
was correlated with lymphocyte counts at presentation, and 
early immune-modulators (corticosteroids or IVIG) induced 
dramatic recovery of severe pneumonic consolidations with-
in a day.99,100 Therefore, it is also acceptable as a new con-
cept that small pathogenic proteins are produced during im-
mune reactions in acute systemic infections (influenza virus 
or M. pneumoniae), not by viruses or mycoplasmas them-
selves, and can induce cytopathic effects on lung tissues by 
hyperactivated immune cells, especially T cells.99 In these 
infections, like strong natural toxins, extremely small 
amounts of pathogenic proteins that have affinity to lung tis-
sues can induce severe lung injury leading to death by am-
plification of a maladjusted immune reaction.
Along with studies for etiologic agents of KD, some in-
vestigators have proposed the immunopathogenesis of KD. 
Recently the study group of Yeung15 presented an interest-
ing model for the pathogenesis of KD using a mouse model 
of KD. They created experimental mice which were able to 
develop coronary arteritis in response to intraperitoneal in-
jections of Lactobacillus casei cell wall extract (LCWE). 
This murine model of KD is similar to human KD includ-
ing the aspect of massive activation of immune cells, dis-
ease susceptibility in the young and a similar pathology of 
coronary arteritis, although replication of the disease is not 
perfect. They observed that immune cells began to appear 
in cardiac tissue at day 3 after LCWE injection, and then 
more immune cells, mainly T cells, infiltrated around the 
arteries and peaked at day 28. Also, disruption of the intima 
and media as well as aneurysm formation were observed at 
day 42.15,101 They postulated that T cells have a crucial role 
in the pathogenesis of KD. A superantigen in LCWE acti-
vates massive T-cell clones, and T-cells survive from apop-
tosis by a co-stimulatory signal on coronary endothelial 
cells as transformed antigen presentation cells. TLR2 on 
endothelial cells and a corresponding ligand in LCWE may 
in part intensify co-stimulation expression on the cells. Ac-
tivated T cells continued to produce cytokines including 
TNF-α and IFN-γ, causing a cytokine imbalance in local le-
sions, that may be responsible for vessel wall injuries. It 
may be true that T cells have crucial roles in animal KD and 
in human KD, since adaptive immune deficiency mice (re-
combination activating gene1 knockout mice) and TCR 
proteins in KD have affinity mainly to endothelial cells of 
coronary arteries, and bind to the receptors on endothelial 
cells. This process is directly toxic to the endothelial cells 
and/or produces new proteins including inflammatory me-
diators through signal transduction pathways to the nucleus. 
These mediators from the affected cells are a signal for the 
recruitment of immune cells (Fig. 3B). To control the patho-
genic proteins and/or the new proteins from the injured 
cells, immune cells, especially T cells for small proteins, are 
recruited and activated. Because there is a time-gap for the 
appearance of specific immune cell clones (specific T cells 
and B cells) in an immune reaction, this reaction may be 
conducted by non-specific T cells and non-specific antibod-
ies initially, until the specific T cell clones and specific anti-
bodies that can efficiently control pathogenic proteins are 
produced. The activated immune cells during this immune 
reaction (in the process of protein control) produce various 
inflammatory cytokines and counter-inflammatory cyto-
kines, and a cytokine imbalance may be associated with the 
endothelial cell injury in KD. The substances from the in-
jured cells recruit more immune cells with more cytokine 
production. Some cytokines such as TNF-α induce other 
proteins including matrix metalloproteinase (MMP) 9, which 
is toxic to neighboring cells, and aggravate tissue injuries 
(Fig. 3C). Other substances released from the initial focus 
and/or the substances released from the injured lesions and 
cytokines spread via systemic circulation and induce the ini-
tial clinical manifestations of KD, including fever and other 
diagnostic clinical signs, and other rare manifestations of 
KD. The substances inducing extra-coronary manifestations 
including skin rashes and arthritis in KD are controlled by 
immune cells, and they may not contain the pathogenic pro-
teins which induce a signal to tissue injury. After the emer-
gence of specific T cell clones and specific antibodies for 
pathogenic proteins, inflammation ceases and a repair reac-
tion begins with the immune cells and regenerating cells 
(Fig. 3D). Briefly, the genetic determination of KD suscepti-
bility may depend on a defect in the immune cells to detect 
and remove pathogenic proteins from initial infections. Also, 
severity of the disease may depend on the amount of patho-
genic proteins with corresponding hyperactivity of immune 
cells and the time-period for emergence of specific immune 
cells against pathogenic proteins. The immunopathogenesis 
of ARF or other immune-mediated disease could be ex-
plained similarly by this hypothesis. Accordingly, pathogen-
ic proteins, affected target cells, the subset of corresponding 
immune cells and the kinds of cytokines and other sub-Kyung-Yil Lee, et al.
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rameters may help shorten the fever duration of the severe-
ly affected patients. A hypothetical pathogenesis of KD is 
proposed using the premise of a “protein homeostasis sys-
tem” of the host. Hyperactive immune cells, especially T 
cells, with excessive cytokines may be responsible for tis-
sue injury as well as for tissue reconstruction according to 
this hypothesis. Further developed tools including bioinfor-
matics of candidate genes and proteomics may be needed 
for establishing more detailed explanations on the patho-
genesis as well as developing diagnostic tests and improved 
treatments for the prevention of KD.
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